Suntrust Banks’s Corcept Therapeutics CORT Stock Holding History

Suntrust Banks’s Portfolio CORT Stock Details CORT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-11,837	Closed	-$85K	–	1300
2016 Q4	$85K	Buy	+11,837	New	+$92.8K	﹤0.01%	1544
2016 Q2	–	Sell	-29,710	Closed	-$139K	–	1506
2016 Q1	$139K	Sell	29,710 -10,000	-25%	-$39K	﹤0.01%	1395
2015 Q4	$197K	Hold	39,710	–	–	﹤0.01%	1327
2015 Q3	$149K	Hold	39,710	–	–	﹤0.01%	1195
2015 Q2	$238K	Sell	39,710 -25,000	-39%	-$153K	﹤0.01%	1107
2015 Q1	$362K	Sell	64,710 -7,500	-10%	-$27.2K	﹤0.01%	955
2014 Q4	$216K	Sell	72,210 -36,000	-33%	-$110K	﹤0.01%	1106
2014 Q3	$290K	Hold	108,210	–	–	﹤0.01%	1180
2014 Q2	$302K	Buy	+108,210	New	+$319K	﹤0.01%	1200

Other funds holding CORT

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

ISL

Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Suntrust Banks's CORT Position: Q1 2017 in Review

Suntrust Banks sold out of Corcept Therapeutics (CORT) in Q1 2017, closing a stake of 11,837 shares — an estimated $85K sold.

Suntrust Banks first reported a position in CORT in Q2 2014 and held it in 9 quarters. The position peaked at $362K in Q1 2015. 135 funds tracked by Wall St. Rank hold CORT as of Q1 2017.

Suntrust Banks reported no remaining Corcept Therapeutics position as of Q1 2017 after selling out during the quarter.
Suntrust Banks sold 11,837 Corcept Therapeutics shares in Q1 2017, an estimated $85K.
Suntrust Banks first reported a position in Corcept Therapeutics in Q2 2014 and held it in 9 quarters.
Suntrust Banks's Corcept Therapeutics position peaked at $362K in Q1 2015.
135 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q1 2017.

Based on Suntrust Banks's 13F filing for Q1 2017, filed 3 May 2017.